The Horizon Prize, powered by MIT Solve, seeks technology-based solutions that improve the quality of life of people who have been diagnosed with a rare disease, explained Rachael Drew, Portfolio Lead for MIT Solve, before Holly Copeland, Senior Director of Corporate Social Responsibility, Sustainability & Impact at Horizon Therapeutics, awarded this year’s prize to EB Research Partnership. Taking the stage, Michael Hund, CEO of EB Research Partnership, described his organization’s mission to end Epidermolysis Bullosa (EB), a devastating genetic disorder that affects approximately 500,000 people worldwide. Caused by a single genetic mutation, they hope to cure EB by 2030. Their pioneering business model, which centralizes patient data, resources, and clinical trial information, can be scaled to address other rare diseases. Putting people at the center of care allows the right treatment to get to the right patient at the right time, Hund continued. He intends for his organization to make EB and other rare diseases history, and show the world how cures can be found.
“We work to drive innovation to solve world challenges.”
Rachael Drew, Portfolio Lead, MIT Solve
“Together we will make EB and rare disease history, and in the process show the world how cures are found.”
Michael Hund, CEO, EB Research Partnership
English
Arabic
Chinese (Simplified)
French
German
Greek
Italian
Japanese
Portuguese
Spanish